Nikan Teb Kimia

As a knowledge-based pharmaceutical company, Nitka is focused on improving patients' lives by identifying, developing and commercializing new products. Our main goal is to produce products based on hyaluronic acid molecule for non-invasive orthopedic treatments.

As part of its ongoing commitment to improving patients' lives, Nitka is committed to producing products in a variety of therapeutic fields. This realization is possible by improving the sales quality of the company's current products and focusing on development in various fields of treatment.

OUR CULTURE

At Nitka, we have embedded a culture of patient satisfaction that all our personnel strongly believe in and always follow. This is possible by defining the company's mission, vision and values. Each member of Nitka team strives to achieve this important goal of improving patients' lives.

History of Nitka

2009 Establishment of the company
2010 Design of business model
2010 Formation of research team
2013 Completion of Synogel 1.5%
2014 Successful completion of industrial production
2015 Establishment of international cooperation for the production of a contract with the Italian company Savio
2015 Obtaining a production license of Synogel 1.5% from the Food and Drug Administration
2016 Production of Synogel 1.5% in Savio
2017 Supply of Synogel 1.5% to the pharmaceutical market of Iran country
2017 Obtaining a production license of Synogel 1.6% and Viscor 2%
2018 Supply of Synogel 1.6% and Viscor 2% to the pharmaceutical market of Iran country

Nitka goals

Nitka's goal is to focus on three important subjects:

Patient satisfaction, efforts to improve patients' lives

Creating a suitable environment for work

Centering Nitka values; Cooperation, honesty, passion for work and innovation

Nikan Teb Kimia Company

This email address is being protected from spambots. You need JavaScript enabled to view it.
nikan_teb_kimia
021-22028822

All logos and trademarks on this site are to manage the Nitkaco reserved

web design